FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

It is estimated that one in five people in Northern Ireland are living with a chronic pain condition like arthritis, ...

Some forms of exercise training and pharmacological-based interventions may improve fibromyalgia-related sleep disturbances, though evidence is limited.

Disturbed sleep is a prominent feature of fibromyalgia symptomatology and has been proposed as one of the core symptoms that should be systematically assessed in clinical trials for the treatment ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

A recently completed study found that certain terpenes in Cannabis sativa are effective at relieving post-surgical and fibromyalgia pain in preclinical models.

Clifton was diagnosed with anxiety and depression as a teen. She used her mental diagnoses and her physical diagnosis; ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be ...

Terpenes from the Cannabis sativa plant may be a viable medication for fibromyalgia and post-surgical pain relief, according ...